|1.||Godfrey, F M: 1 article (09/2000)|
|2.||Chan, W N: 1 article (09/2000)|
|3.||Herdon, H J: 1 article (09/2000)|
10/31/1996 - "The excellent anticonvulsant profile of SB 204269, combined with the identification of a unique binding site for the compound, suggest that it has potential clinical utility as a novel treatment for epilepsy."
09/01/1998 - "SB-204269 is an anticonvulsant agent under development by SmithKline Beecham, It is in phase II clinical trials as a potential treatment for epilepsy . "
08/01/1997 - "Profile of SB-204269, a mechanistically novel anticonvulsant drug, in rat models of focal and generalized epileptic seizures."
08/01/1997 - "2. Studies have now been undertaken to determine the effects of SB-204269 in a range of seizure models and tests of neurological deficits in rats. "
09/01/2000 - "SB-204269 (trans-(+)-6-acetyl-4S-(4-fluorobenzoylamino)-3, 4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3R-ol) shows anticonvulsant activity in a range of animal seizure models, with a high therapeutic index and a lack of side-effects. "
08/01/1997 - "The affinities of analogues of SB-204269 for binding can be related to their activities in the mouse maximal electroshock seizure threshold (MEST) test of anticonvulsant action. "
08/01/1997 - "9. The overall efficacy profile in rodent seizure models, together with a minimal liability for inducing neurological impairment and an apparently unique mechanism of action, highlight the therapeutic potential of SB-204269 for the treatment of refractory partial and generalized tonic-clonic seizures."
08/01/1997 - "4. SB-204269 also selectively reduced focal electrographic seizure activity in an in vitro elevated K+ rat hippocampal slice model at concentrations (0.1-10 microM) that had no effect on normal synaptic activity and neuronal excitability. "
|4.||Anticonvulsants (Antiepileptic Drugs)